Reshma Shringarpure

机构：Spero Therapeutics (United States) · ORCID：0000-0001-5936-0447

发表论文 114 篇 · 总被引 8090 次 · h-index 41

代表论文

• Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial (2023 · ˜The œLancet. Gastroenterology & hepatology · 被引 256)
• Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study (2021 · Journal of Hepatology · 被引 160)
• Efruxifermin in Compensated Liver Cirrhosis Caused by MASH (2025 · New England Journal of Medicine · 被引 111)
• A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis (2022 · JHEP Reports · 被引 105)
• Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study (2024 · Clinical Gastroenterology and Hepatology · 被引 92)
• Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial (2025 · The Lancet · 被引 57)